Importantly, these autoantibodies could distinguish AD from other neurodegenerative diseases and outperformed amyloid and tau protein concentrations in cerebrospinal fluid in predicting cognitive decline (p < 0.001). The gene discussed is MAPT; the disease is Alzheimer disease.